Ketchum nabs pain relief brief

Ketchum has been appoin­ted by Napp Pharmaceuticals to handle UK public ­relations for BuTrans – a pain relief treatment for sufferers of osteo­arthritis and joint pain.

The agency was appointed following a four-way pitch and replaces Axon Communications, which had held the account since the product’s launch in 2005.

Axon did not repitch for the work.

The Ketchum account team is headed by account director Peter Impey.

Work by the team will ­focus on the ease of use of the treatment, which is in patch form and provides pain relief for up to seven days.

Impey said that another focus will be on the benefits of the treatment in a climate of restrictions in the pain management sector.

This has included the high- profile withdrawals of Vioxx and coproxamol, as well as recent guidance by NICE warning against the use of non-steroidal anti-inflammatories.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in